



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/113104/2013

European Medicines Agency decision

P/0052/2013

of 1 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for asfotase alfa (EMEA-000987-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0052/2013

of 1 March 2013

on the agreement of a paediatric investigation plan and on the granting of a deferral for asfotase alfa (EMA-000987-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Alexion Europe SAS on 20 July 2010 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 February 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for asfotase alfa, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for asfotase alfa, solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Alexion Europe SAS, 25 Boulevard de l'Amiral Bruix, 75016 – Paris, France.

Done at London, 1 March 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/752139/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-000987-PIP01-10

Scope of the application

Active substance(s):

Asfotase alfa

Condition(s):

Treatment of hypophosphatasia

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

Alexion Europe SAS

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Alexion Europe SAS submitted for agreement to the European Medicines Agency on 20 July 2010 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 15 September 2010.

Supplementary information was provided by the applicant on 19 November 2012. The applicant proposed modifications to the paediatric investigation plan and requested a deferral.

A meeting with the Paediatric Committee took place on 07 February 2013.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 8 February 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition: treatment of hypophosphatasia

2.1.1. Indication(s) targeted by the PIP

Treatment of hypophosphatasia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection.

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1 Development of appropriate strengths solution of asfotase alfa for subcutaneous use for all subsets of the paediatric population: 40 mg/mL and 100 mg/mL.
Non-clinical	0	Not applicable.
Clinical	10	Measure 2 Population pharmacokinetics and exposure-response modelling to quantify the population pharmacokinetics of asfotase-alfa, to quantify the relationship between asfotase-alfa exposure and plasma inorganic pyrophosphate and Pyridoxal 5' phosphate biomarkers and to integrate the pharmacokinetic model and exposure-response relationships to support dosing recommendations for asfotase-alfa in specific hypophosphatasia treatment populations. Measure 3 Open label, single arm, exploratory trial to evaluate the safety, tolerability, pharmacokinetics and pharmacology of asfotase alfa intravenous infusion and subcutaneous injection in children from birth to less than 4 years of age with severe hypophosphatasia (ENB-002-08).

Area	Number of measures	Description
		Measure 4 Open label, single arm, exploratory extension study of Measure 3 to evaluate the safety, tolerability, pharmacokinetics and pharmacology of asfotase alfa intravenous infusion and subcutaneous injection in children with severe hypophosphatasia (ENB-003-08). Measure 5 Open-label trial to evaluate safety, efficacy, survival, growth, development and pharmacokinetics of asfotase alfa subcutaneous injection in children from birth to less than 6 years of age with severe hypophosphatasia (ENB-0010-10). Measure 6 Retrospective, non-interventional epidemiologic study of the natural history to evaluate overall survival in patients with severe perinatal and infantile hypophosphatasia and compare outcomes to those of the interventional studies with asfotase alfa of Measure 3 / 4 and 5 (ENB-011-10). Measure 7 Open-label, dose-ranging, historical control study to evaluate the safety, activity, pharmacokinetics and pharmacodynamics of asfotase alfa subcutaneous injection in paediatric hypophosphatasia patients from 5 to less than 13 years and Tanner stage of 2 or less (prepubescent) with open growth plates with perinatal/infantile and childhood onset (ENB-006-09). Measure 8 Open-label, dose-ranging, historical control, extension study of Measure 7 to evaluate the long-term safety, activity, pharmacokinetics and pharmacodynamics of asfotase alfa subcutaneous injection in paediatric hypophosphatasia patients with perinatal/infantile and childhood onset (ENB-008-09). Measure 9 Randomized, open-label, dose-ranging concurrent control study to evaluate the safety, pharmacokinetics, pharmacodynamics and activity of asfotase alfa in adolescents (and adults) with perinatal/infantile and childhood onset hypophosphatasia (ENB-009-10). Measure 10 Double-blind, placebo-controlled, randomized, multicentre, 6-month study with an open label extension treatment period to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of asfotase alfa in patients from 3 years of age to Tanner stage of 2 or less (prepubescent) with open growth plates with childhood onset hypophosphatasia (ENB-014-12).

Area	Number of measures	Description
		Measure 11 Measure to extrapolate efficacy to children from 6 months to below 3 years of age with juvenile onset HPP. Analysis of existing in house data on paediatric patients 6 months to below 3 years of age with perinatal/infantile onset HPP and children aged 3 years and above with juvenile onset hypophosphatasia.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2017.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes